Posted by Michael Wonder on 14 Dec 2016
Somatropin for patients under 2 years with Prader-Willi Syndrome
14 December 2016 - PHARMAC is pleased to announce that somatropin (human growth hormone) will be fully funded for patients with Prader-Willi syndrome under the age of 2 years, subject to certain clinical criteria being met, from 1 January 2017.
Widened access to somatropin for patients with Prader-Willi syndrome under the age of 2 years was the subject of a consultation letter issued in May 2015. No decision was made in 2015 as it was determined that further clinical advice was needed on the issues raised during consultation before a decision could be made.
Clinical advice has now been sought and this advice is reflected in the new criteria.
